Amylin analogue as an antidiabetic agent

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 3, 2005, Pages 151-154

  Day, Caroline ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Amylin; Injections; Pramlintide; Type 1 diabetes; Type 2 diabetes

Indexed keywords

AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON; INSULIN; PRAMLINTIDE;

AREA POSTREMA; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DIABETES CONTROL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SATIETY; STOMACH EMPTYING; UNITED STATES;

EID: 21644452171     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050030701     Document Type: Article

References (14)

1. Bailey CJ. New drugs for the treatment of diabetes mellitus in DeFronzo RA, Ferrannini E, Keen H, Zimmet P (eds). International textbook of diabetes mellitus, 3rd edn, John Wiley and Sons Ltd, Chichester, 2004, pp951-79.
2. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004;47:157-69.
3. In't Veld PA, Zhang F, Madsen OD, Kloppel G. Islet amyloid polypeptide immunoreactivity in the human fetal pancreas. Diabetologia 1992;35: 272-6.
4. Koda JE, Fineman MS, Kolterman OG, Caro JF. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes 1995; 44(suppl 1):238A.
5. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Current Pharmaceutical Design 2001;7:1353-73.
6. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002;20:137-44.
7. Fineman M, Koda J, Lolterman O. Subcutaneous administration of a human amylin analogue suppresses postprandial plasma glucagon concentrations in type 1 diabetic patients. Diabetes 1998; 47(suppl 1):A89.
8. Kong MF, Stubbs TA, King P et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998;41:577-83.
9. Symlin prescriber information. www.symlin.com/docs/Symlin_PI_and_Med_Guide.pdf
10. Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 2003;37:1082-9.
11. Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 2 diabetes. Diabetes Care 2002;25: 724-30.
12. Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002;4:63-5.
13. Heptulla RA, Rodriquez IM, Bomgaars L, Haymond MW. The role of amylin and glucagons in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005;54:1100-07.
14. Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-48.